AtaCor Medical announced today that it entered a financing worth up to $75 million to support its U.S. FDA pivotal study.

Researchers report favorable safety and efficacy for a combination device after implantation and at 6 months follow-up among ...

Danicamtiv is an investigational selective agonist of cardiac myosin, intended to help myocyte contraction by enhancing ...

The Integra-D trial shows the device, which provides cardiac contractility modulation and defibrillation, also eases symptoms ...

Current guidelines recommend pulmonary-vein isolation by means of catheter ablation as treatment for drug-refractory paroxysmal atrial fibrillation. Radiofrequency ablation is the most common method, ...